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Rabiesnt in anti-viral responses and in coordinating the innate immune response. Here
we explore the use of interferon-β to adjuvant the response to a rabies virus (RV) vaccine vector expressing
both HIV-1 Gag and IFN-β. Viral load and immune responses of immunized mice were analyzed over time.
Our results indicate that the RV expressing IFN-β (IFN(+)) is highly attenuated when compared to control RV
and demonstrate that the expression of IFN-β reduces viral replication approximately 100-fold. Despite the
decrease in replication, those mice immunized with the IFN(+) RV had a signiﬁcantly greater number of
activated CD8+ T cells. The increased activation of CD8+ T cells was dependent on IFN-β signaling, as we saw
no difference following infection of IFNAR−/− mice. Although mice immunized with IFN(+) have a greater
primary immune response than controls, immunized mice that were challenged with vaccinia-expressing
Gag had no signiﬁcant difference in the number or functionality of CD8+ T cells. The increased CD8+ T cell
activation in the presence of IFN-β, even with greatly reduced viral replication, indicates the beneﬁcial effect
of IFN-β for the host.
© 2008 Elsevier Inc. All rights reserved.IntroductionTraditional vaccine approaches, such as live-attenuated viruses,
have been very successful in providing immunity to some of
mankind's largest microbial threats. One such success story was the
use of an attenuated vaccinia virus to immunize people against
smallpox infection (Parrino and Graham, 2006). However, similar
approaches cannot be used or have failed to control other infectious
diseases, such as HIV-1. Thus, vaccine development requires novel
approaches and potentially the use of a molecular adjuvant to increase
immune response (Letvin, 2006).
Live attenuated vaccine vectors have the greatest potential for
generating broad-scope immunity and their usefulness has been
shown in different settings. We have generated a vaccine vector based
on attenuated Rabies virus (RV) expressing HIV-1 or SIV antigens that
has proven to be highly immunogenic in mice and has protected non-
human primates from a AIDS-like disease (McGettigan et al., 2001;
McKenna et al., 2007).
RV is an envelopednon-segmentednegative strandRNAvirus of the
Rhabdoviridae family. Although wild type RV almost always causes a
fatal CNS disease inmammalian species (Dietzschold et al., 2003), in its
attenuated form, RVhas proved to be an excellent vaccine vector (Faber
et al., 2005; McGettigan et al., 2003b; McKenna et al., 2007; Siler et al.,
2002). Furthermore, attenuated RV has been shown to induce both a9, Philadelphia, PA 19107, USA.
Schnell).
l rights reserved.strong cellular and humoral immune response to foreign genes
(McGettigan et al., 2003a; McKenna et al., 2007, 2003). RV has a
relatively simple genome organization encoding ﬁve structural
proteins: a nucleoprotein (N), a phosphoprotein (P), a matrix protein
(M), a glycoprotein (G), and an RNA-dependent RNA polymerase (L).
RV-N encapsidates the viral RNA and together with RV-P and
polymerase L composes the ribonucleoprotein (RNP) complex. RV-M
bridges the RNP complex with the transmembrane domain of RV-G
(Mebatsion et al., 1999). Both RV-M and RV-G facilitate virion budding
from an infected cell (Mebatsion et al., 1996, 1999).
The RV lifecycle is thought to be sensitive to several anti-viral
proteins that are induced by type I interferon (IFN) and thus, RV has
developed at least two mechanisms by which it can antagonize type I
IFN induction and signaling. In addition to serving as the non-catalytic
cofactor to polymerase L, RV-P also inhibits the phosphorylation of
IRF-3 at serine-386 by interfering with TBK-1 (Brzozka et al., 2005).
Furthermore, the C-terminal domain of RV-P can bind to the coil–coil
domain of Stat1 and efﬁciently prevent the nuclear accumulation of
Stat1 (Brzozka et al., 2006; Vidy et al., 2005, 2007). Thus, RV-P
interferes with both the induction and signaling of type I interferon.
Type I interferon, although originally recognized for its anti-viral
properties, has recently gained recognition for its role in coordinating
the innate and adaptive immune responses. Type I IFN expressionmay
bias immune responses toward Th1 responses (Wenner et al., 1996),
and, in addition, IFN-α/β plays an important role in the clonal
expansion of antigen-speciﬁc CD8+ T cells. Adoptive transfer of
interferon receptor knockout (IFNAR−/−) CD8+ T cells into wild type
hosts highlighted the necessity of IFN-α/β signaling in Tcells to induce
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(Kolumam et al., 2005).
Type I IFN not only affects T cell responses, but, has also been
shown to augment the immune response by activating antigen
presenting cells (APC). Dendritic cell (DC) maturation following
infection with LCMV (Montoya et al., 2005) and Herpes simplex
virus type-1 (Pollara et al., 2004) has been shown to be type I IFN
dependent. Additionally, subsequent to transfection with two
recombinant adenovirus (Ad) vectors, it was seen that DCs
upregulated the expression of phenotypic activation markers. The
increase was independent of viral replication and toll like receptor
(TLR) signaling. However, there was only a marginal increase of co-
stimulatory molecules on the surface of BM-DC derived from IFNAR
−/− mice, suggesting that the maturation of Ad-transduced cells
was dependent on type I IFN signaling (Hensley et al., 2005).
Furthermore, following maturation in the presence of type I
interferon and GM-CSF, monocyte-derived DCs more effectively
stimulate an antigen-speciﬁc CD8+ T cell response than DCs
matured with GM-CSF and IL-4 (Santodonato et al., 2003).
It is apparent that IFN-α/β plays an important role in directing the
adaptive immune response. This function also suggests that it may be
a valuable adjuvant in vaccine development. However, much of the
work supporting the immune-modifying functions of IFN-β have
been done in vitro; therefore, the potential use of IFN as an adjuvant
in vaccine development needs to be further investigated. In an
attempt to induce IFN-α/β expression in a vaccine for respiratory
syncytial virus (RSV), Martinez-Sobrido et al. inserted the RSV-F
protein into a Newcastle disease virus (NDV) vaccine vector. Although
the recombinant virus increased IFN-α/β levels, as predicted, and
protected mice against RSV challenge the mechanism of protection
was unclear, because similar protection was seen in IFNAR−/− and
wild type mice (Martinez-Sobrido et al., 2006). When combining
multiple viral proteins, it may be impossible to distinguish the direct
effects of the interferon from the immunological response to the
additional protein. Furthermore, different viruses have several
distinct features in addition to their ability to induce IFN, which
make results difﬁcult to analyze. Here we use a system in which IFN-
β is expressed by the RV vaccine vector in order to compare the
immune responses induced in the presence or absence of increased
levels of IFN-β.
The use of IFN-β to promote the induction of a stronger CD8+ T
cell response might be beneﬁcial for certain vaccine approaches.
Although little evidence is available to link the beneﬁcial outcome of
a RV infection to increased CTL responses against RV as a vaccine
vector, increased CTL responses to the foreign antigen may be
required. In order to further investigate the potential immune-
enhancing effects of IFN-β, we constructed two recombinant Rabies
viruses, one expressing both HIV-1 Gag and IFN-β and the other
expressing HIV-1 Gag and IFN-β minus the ATG start codon. Our
data support the hypothesis that IFN-β works at the interface of the
innate and adaptive immune response by sustaining the pool of
activated antigen-speciﬁc CD8+ lymphocytes. Thus, in addition to
controlling viral replication (a well-studied effect of type I IFN), we
provide evidence that IFN-β also directs the cells of the adaptive
immune system to adequately respond to a pathogen. Elucidating
the immune-modifying effects of type I IFN is important in
determining whether the addition of this cytokine can enhance
the cellular response and increase the potency of RV-based vaccine
vectors.
Results
Construction and characterization of the recombinant RV
To investigate the effect of type I interferon on the adaptive
immune response, we used a previously well-characterized RVvaccine vector encoding HIV-1 Gag (Fig. 1A, denoted BNSP-Gag)
(McGettigan et al., 2001). For our purposes, the gene encoding mouse
IFN-β was introduced between the RV-G and L genes resulting in
virus that expressed both HIV-1 Gag and IFN-β (Fig. 1A, denoted IFN
(+)). Of note, it is well established that the expression of an additional
gene can change the growth characteristics of RV (McGettigan et al.,
2006). Thus, in order to have the proper control, we also cloned the
mouse IFN-β gene without the ATG start codon between the RV-G
and L genes (Fig. 1A, denoted IFN(−)). Recombinant viruses were
recovered by standard methods as previously described (Tan et al.,
2007).
We then evaluated the expression of IFN-β by the two
recombinant RVs IFN(+) and IFN(−). Production of IFN-β was
quantiﬁed in viral supernatant via ELISA 48 h post infection (Fig.
1B). We detected only background levels of IFN-β in the super-
natants of BSR cells infected with IFN(−), presumably due to the
IFN antagonistic activity of RV-P (Brzozka et al., 2005; Brzozka,
Finke, and Conzelmann, 2006; Vidy et al., 2005, 2007). On the
other hand, BSR cells infected with the IFN(+) virus produced
approximately 3.5 μg/ml IFN-β, which is a 1000-fold increase over
background. Next, we aimed to assess the biological functionality of
the IFN-β expressed by the recombinant RV. Brieﬂy, we infected
BSR cells with IFN(+), IFN(−) or BNSP for 48 h. The supernatant
from each sample was then collected and UV-inactivated. Serial
dilutions of the supernatants were then used to pre-treat mouse
NA cells for 24 h prior to infecting the NA cells with recombinant
VSV expressing GFP (Stojdl et al., 2003). Five hours after infection
with VSV-GFP, NA cells were analyzed for expression of GFP, a
marker for VSV replication in our system. Type I IFN is known to
efﬁciently inhibit VSV replication in neurons (Trottier et al., 2005);
thus, if functional IFN-β is present in the supernatant, we should
not see GFP expression. As shown in Fig. 1C, only supernatants
from IFN(+) infected cells efﬁciently inhibited VSV replication,
indicating the presence of functional IFN-β in that sample.
The expression of HIV-1 p55 was determined by immunostain-
ing infected BSR cells. Recombinant RV BNSP IFN(−) and IFN(+)
were analyzed with antibodies directed against RV-N or HIV-1 p24.
The results indicate that all viruses infect the cells (Fig. 1D, anti-RV-
N) and both IFN(−) and IFN(+) RV express HIV-1 Gag (Fig. 1D, anti-
HIV-1 p24).
Characterization of recombinant viruses growth kinetics
To determine whether the expression of both IFN-β and HIV-1
Gag in the RV genome altered the growth kinetics of RV we
analyzed viral growth by multi-step and one-step growth curves. It
is well documented that IFN-β is a potent anti-viral; therefore, we
analyzed growth kinetics on both type I IFN responsive and non-
responsive cells. It was determined that both NA and BSR cells can
produce type I IFN following Sendai virus infection. Of the two,
however, only NA cells are responsive to mouse IFN-β and, thus,
able to inhibit VSV replication (data not shown). Cells were infected
with an MOI of 0.1 (multi-step) or 10 (one-step). Aliquots of the
supernatants were collected at various time points, and the titers
were determined. The multi-step and one-step growth curves
derived from infected BSR cells illustrated that IFN(+) and IFN(−)
viruses grew with similar kinetics and to relatively equal titers (Figs.
2A, C), indicating that the expression of IFN-β did not affect viral
growth by a type I IFN independent mechanism. Of note, the titer
for both IFN(+) and IFN(−) viruses was about 10-fold less than the
titer of the parent virus strain, BNSP-Gag, at all time points
presumably due to the insertion of the IFN-β gene between RV-G
and RV-L. However, when IFN-β sensitive cells were used, there was
a signiﬁcant difference in the growth kinetics of IFN(+) and IFN(−)
RV. For both one-step and multi-step growth curves there is a delay
in viral growth and approximately a 2.5 to 3 log decrease in the ﬁnal
Fig. 1. Construction of recombinant RV and expression of Gag and IFN-β. (A) We cloned mouse IFN-β (IFN(+)) or mouse IFN-β lacking the ATG start codon (IFN(−)) into the vaccine RV
strain BNSP-Gag, which expresses HIV-1 Gag. Recovered viruses were analyzed for expression of the IFN-β by ELISA (B) and the functionality of the IFN-βwas determined by a VSV
protection assay (C). For this approach, BSR cells were infected, and at 48 hpi the supernatant was UV-inactivated. NA cells were pre-treated with UV-inactivated supernatant at a
dilution of 1:10 or 1:1000 for 24 h and then infected with VSV-GFP for 5 h. GFP expression, an indication of VSV replication, is seen by green ﬂuorescence. (D) Recovered viruses were
also analyzed for expression of HIV-1 p55 by immunoﬂuorescent staining. Cells were infected with recombinant RV and stained for RV-N or HIV-1 p55.
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exhibits anti-viral properties when grown on IFN sensitive cells.
Immunogenicity of recombinant RV in Balb/c mice following mucosal
immunization
In order to characterize how the increased expression of IFN-β
following a RV infection would impact the immunogenicity and
pathogenicity of RV vaccine vectors, BALB/c mice were immunized
intranasally with 1.5×105 ffu of IFN(+) or IFN(−). We infected the mice
intranasally in order to see the effect on pathogenicity, because it has
been shown that the ﬁrst generation vaccine vector, BNSP-Gag, is
apathogenic after peripheral inoculation while still lethal after
intranasal or intracranial inoculation (McGettigan et al., 2003b). We
saw that the survival of mice infected with the IFN(+) virus was
signiﬁcantly greater than the survival of those mice infected with the
recombinant RV which did not express IFN-β (Fig. 3A). As expected,this suggested that expression of IFN-β results in increased survival of
IFN(+) immunized mice.
We next sought to determine whether the increased survival was
due to the anti-viral activity or immune-modifying activity of IFN-β.
Again, mice were immunized intranasally with IFN(+) and IFN(−), and
then the brains and the spleens of infected animals were taken at
various times post infection. Viral RNA in the brain was quantiﬁed
using qPCR speciﬁc for RV-N as previously described (Tan et al., 2007).
As shown in Fig. 3B, there was an average 1000-fold decrease in viral
messenger RNA on day 8 and a 100-fold decrease in mRNA on day 12
when mice were infected with the IFN(+) virus as compared to mice
infected with the control IFN(−) virus. Of note, the viral genomic RNA
on day 8, 12, and 15 was about 10-fold lower than the messenger RNA
for each mouse (data not shown). Thus, in vivo IFN-β expression had a
similar attenuating effect on viral growth as was seen in tissue culture
and efﬁciently decreased the viral load during the ﬁrst 12 days of
infection.
Fig. 2. Growth kinetics of recombinant RV. (A, B) For the one-step growth curve BSR cells (A) or NA cells (B) were infected at a high MOI of 10 with recombinant RV to determine the
effect of IFN-β expression on viral production. (C, D) To generate a multi-step growth curve, BSR cells (C) or NA cells (D) were infected with recombinant RV at a lowMOI of 0.01; this
illustrates the effect of IFN-β expression on viral replication and spread.
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evaluate the immune-modifying effect of IFN-β on the RV vaccine
vectors. Due to the low precursor frequency of antigen-speciﬁc cells
in a wild type mouse, we looked at the percentage of activated
cells (CD44hiCD62Llo) in the CD8+ lymphocyte population. This
shows the immune response to the entire vaccine vector and not
just to the HIV-1 gag protein. Surprisingly, we saw that, despite a
large decrease in viral load in IFN(+) infected animals at 8 dpi,
there were similar numbers of activated CD8+ T cells recovered
from IFN(+) and IFN(−) infected animals. Furthermore, at 12 dpi,
there was a signiﬁcant increase in the percentage of activated CD8+
splenocytes in the IFN(+) infected animals despite the 100-fold
decrease in viral antigen (Figs. 3C, D). Thus, although mice infected
with the IFN(+) virus probably had a lower amount of viral antigen
at 8 and 12 dpi due to the anti-viral effects of IFN-β, these mice
had similar (day 8) or signiﬁcantly greater (day 12) CD8+ T cell
responses. In order to determine whether this effect is speciﬁc to
the route of immunization we also looked for T cell activation inthe inguinal lymph nodes and spleens of mice immunized
intramuscularly. Consistent with what was seen after intranasal
immunization, 8 dpi there was no signiﬁcant difference between
the activated T cells found in the IFN(+) and IFN(−) immunized
mice (data not shown). Thus we conclude that during the primary
immune response, IFN-β is acting as an adjuvant for the cellular
immunity.
Type I IFN has also been shown to affect antibody development
following inﬂuenza infection (Heer et al., 2007). To determine the
impact that IFN-β expression has on the humoral immune response in
our vaccine strategy, mice were bled at various times post infection,
and sera was analyzed for RV-G antibodies. It was seen that total IgG
levels increased when the mice began to lose weight (Figs. 4A–D), and
IFN(−) immunized mice had appreciable RV-G IgG levels in their sera
at earlier timepoints than IFN(+) immunized mice. Moreover, three
out of seven IFN(+) mice never developed RV-induced pathology but
also never produced anti-RV antibodies, indicating that the innate
immune response via IFN-β can clear RV infection.We concluded from
Fig. 3. Pathogenicity and immunogenicity of recombinant RV in the primary response to immunization. Micewere immunized intranasally with 1.5×105 ffu of sucrose puriﬁed RV. (A)
Survivorship of themicewasmonitored by a Kaplan–Meier test for signiﬁcance.We saw a signiﬁcant increase in the survival of mice immunized intranasally with IFN(+) as compared
to those immunized with IFN(−). (B) Viral messenger RNA recovered from the brains of infected mice was quantiﬁed using real time PCR at 8, 12, and 15 days after infection.
Signiﬁcantly more virus was detected in the brains of mice infected with IFN(−) virus as compared to mice infected with the IFN(+) virus. (C and D) Despite lower amounts of virus,
mice infectedwith IFN(+) virus had a signiﬁcantly greater percentage of activated (CD44hi CD62Llo) CD8+ Tcells at 12 dpi. One representativemouse from each group is shown (C) and
also the average of 5 mice per group for each time point (D). Horizontal lines indicate the average value and (⁎) indicate a p value of b0.002.
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by viral replication.
To determine whether the delayed kinetics of antibody production
in mice vaccinated with IFN(+) was due to a persistent infection of IFN
(+) RV, we quantiﬁed the viral messenger RNA at day 15 (when mice
ﬁrst exhibited signs of disease) and at 19 dpi (when mice were at their
lowest body weight). We saw that at day 19 the level of viral RNA
message was decreasing and most of the mice have around 102 copies
of viral mRNA/μg RNA (Fig. 4E). Of note, the one mouse that had a high
level of viral messenger RNA 19 dpi had the lowest amount of virus at
15 dpi, thus it is possible that the kinetics of viral replication in that
mouse was highly delayed. Therefore, it seems unlikely that the IFN(+)
virus is persisting long term in themice, but rather the kinetics of viral
replication may be delayed by the addition of IFN-β.
Immunogenicity of recombinant RV in IFNAR−/− mice following mucosal
immunization
In order to establish that the differences seen in BALB/c mice were
dependent on the expression of IFN-β, we repeated the evaluation of
viral load and immunogenicity in interferon receptor knockout (IFNAR−/−) mice. Type I IFN signals through a heterodimeric receptor to
initiate the JAK/ STAT signaling pathway (Randall and Goodbourn,
2008). One of the receptor subunits is knocked out in the IFNAR−/−
mice rendering them unable to initiate the IFN-β signaling cascade
(Muller et al., 1994). Following immunization, the IFNAR−/− mice
receiving either the IFN(+)or the IFN(−) immunization did not show
signiﬁcant differences in survival (Fig. 5A). Likewise, 8 dpi therewas no
signiﬁcant difference in the amount of viral messenger RNA isolated
from the brains ofmice that had been immunizedwith IFN(+) or IFN(−)
vaccine vectors (Fig. 5B). In addition, the percentage of CD44hiCD62Llo
cells in the CD8+ populationwas equal inmice immunizedwith IFN(+)
or IFN(−) (Figs. 5C, D). Taken together, these data suggest that the
differenceswe observed inwild type BALB/cmice immunizedwith IFN
(+) and IFN(−) viruses were due to IFN-α/β signaling.
Increased levels of type I IFN do not increase the activation level of
antigen presenting cells, but may promote increased survival of CD8+ T
cells following antigen encounter
In order to more fully understand the role of IFN-β in the primary
immune response following viral infection, we sought to determine
Fig. 4. Vector speciﬁc IgG antibody formation. Mice were immunized intranasally with 1.5×105 ffu of sucrose puriﬁed IFN(+) RV (A, C, E) or IFN(−) RV (B, D). The weight ﬂuctuations
were monitored over time (A, B) and blood was collected from mice at various times post immunization. (C, D) An ELISA was done to determine the total IgG speciﬁc for RV-G on a
given day. RV-G speciﬁc IgG formation is delayed following immunizationwith IFN(+). (E) Viralmessenger RNA recovered from the brains of IFN(+) infectedmicewas quantiﬁed using
real time PCR at 15 and 19 days after infection to determine if the infection persisted. Horizontal lines indicate the average value.
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activation. Several groups have seen that IFN-β acts on antigen
presenting cells, such as macrophages and dendritic cells, to induce
the upregulation of co-stimulatory molecules that, in turn, may
generate a greater T cell response. Alternately, the IFN-β may act
directly on the CD8+ T cell to contribute to their activation.
To test the ﬁrst hypothesis, we infected a macrophage cell line
(Raw264.7) or a dendritic (JAWSII) cell line with IFN(+) or IFN(−)
viruses. At various hours post infection, we analyzed the activation of
the APC by determining the expression of CD80 or CD86. Following
infection of macrophage cells with either IFN(+) or IFN(−), there was a
dramatic upregulation of CD80 by 48 hpi (Fig. 6A). However, therewas
no signiﬁcant difference in the fold increase over uninfected cells inCD80 expression when comparing IFN(+) and IFN(−) infected cells at
any time point. Similarly, we saw that following infection of JAWSII
cells with either IFN(+) or IFN(−) RV equally induced the upregulation
of CD86 expression (Fig. 6B). In order to more clearly distinguish the
effect of IFN-β from the RV infection a supplementary experiment was
performed in which the supernatant from IFN(+) or IFN(−) infected
JAWSII cells was used to activate uninfected JAWSII cells. After 24 or
48 h, there was no signiﬁcant difference in the activation state, as
determined by expression of CD80 and CD86, of JAWSII cells treated
with UV-inactivated supernatant from IFN(+) or IFN(−) infected cells
compared to cells treated with uninfected supernatant. Thus, it seems
that incorporating IFN-β into the RV construct does not signiﬁcantly
increase DC activation. Therefore, it seems unlikely that the difference
Fig. 5. Pathogenicity and immunogenicity of recombinant RV vectors in IFNAR−/−mice. Mice were immunized intranasally with 1.5×105 ffu of sucrose puriﬁed RV. (A) Survivorship of
the mice was monitored by a Kaplan–Meier test for signiﬁcance. We saw no signiﬁcant difference in the survival of mice immunized with IFN(+) or IFN(−). (B) Viral messenger RNA
recovered from the brains of infected mice was quantiﬁed using real time PCR 8 days after infection. There was no signiﬁcant difference in the viral load found in mice immunized
with IFN(+) or IFN(−). (C and D) Therewas no difference in the activation (CD44hi CD62Llo) of CD8+ Tcells 8 or 12 dpi. One representativemouse from each group is shown (C) and also
the average of 5 mice per group for each time point (D). Horizontal lines indicate the average value.
232 E.J. Faul et al. / Virology 382 (2008) 226–238we observed in CD8+ T cell activation was a result of increased co-
stimulation by APCs.
IFN-β does not appear to increase maturation of APCs; therefore,
we next investigated the impact that IFN-β has on the antigen-speciﬁc
CD8+ T cell population in our vaccine strategy. To determine the direct
effect of IFN-β on T cells, we developed a transfer model inwhich all of
the T cells in the mouse were either wild type (responsive to IFN) or
IFNAR−/− (non-responsive to IFN). Brieﬂy, we isolated CD3+ T cells
from BALB/c or IFNAR−/− mice and then transferred 3×106 cells
intraperitoneally into Nude mice (Fig. 7A). Nude mice have a very
small number of mature α/β-T cells with limited functionality in the
periphery (Kindred, 1979; Kishihara et al., 1987; Yoshikai et al., 1986).
In this transfer model, the only T cells able to respond to infection
are those we transferred to the mice one day prior to infection with
the IFN(+) virus. In analyzing the splenocytes, we saw no difference in
the percentage of activated CD8+ T cells in the spleens of BALB/c or
IFNAR−/− recipient mice 12 dpi (Fig. 7B). However, we did notice that
the total number of CD8+ cells recovered from the BALB/c recipient
mice tended to be greater than the number recovered from the IFNAR
−/− mice (Fig. 7C). This trend approached signiﬁcance when compar-
ing CD8+ Tcell number (p=0.0661), however was not signiﬁcant whencomparing CD4+ T cell number (p=0.3326). We conclude that IFN-β
signaling may be important to sustain the population of antigen-
speciﬁc T cells following infection.
Recall response to HIV-1 Gag
The proof of principle in all vaccine studies is a challenge model. To
assess the effect of IFN-β on the development of long-term memory
cells, a key requirement for any vaccine, we intramuscularly (i.m.)
immunizedmicewith 106 ffu of IFN(+) or IFN(−). It has been previously
shown that the peripheral injection of BNSP based vaccine vectors is
not pathogenic in immune competentmice (McGettigan et al., 2003b).
Likewise, no clinical signs of rabies were detected following i.m.
immunization with the IFN(+) or IFN(−) vectors (data not shown).
Immunized BALB/c mice were rested for at least 60 days and then
challenged intraperitoneally (i.p) with 106 plaque forming units (pfu)
of vaccinia virus expressing HIV-1 Gag (vv-Gag). The HIV-1 Gag
speciﬁc recall response was analyzed 5 days later by evaluating
expression of Gag speciﬁc T cell receptors (TCR) with an AMQMLKETI-
H2Kd speciﬁc tetramer. Additionally, the functionality of the memory
cells was determined by intracellular cytokine staining.
Fig. 6. The effect of IFN-β on antigenpresenting cell activation. (A)Macrophage cells (Raw264.7) increased expression of CD80 over time following infection at anMOI of 10with IFN(+)
and IFN(−). The left panel shows one representative experiment at 72 hpi. The right panel shows the average fold increase in MFI over the uninfected sample (representative of 3
independent experiments). (B) The expression of CD86 on dendritic cell line JAWSII over time following infection at an MOI of 10 with IFN(+) or IFN(−) RV. The left panel shows one
representative experiment at 48 hpi. The right panel shows the average fold increase in MFI over the uninfected sample (2 independent experiments).
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positive CD8+ T cells present following immunization with IFN(+) or
IFN(−) RV (Fig. 8A). However, the IFN(+) immunized mice seemed to
fall into 2 groups: high responders and low responders (percentage of
tetramer+ CD8+ cells less than 10%). When considering the function-
ality the CD8+ T cells, we saw no difference in the induction of
cytokines between IFN(+) and IFN(−) immunized animals (Fig. 8B). The
expression of IFN-γ and IL-4 was induced at the highest level, while
very little IL-2 an IL-10 was induced. Taken together, these results
indicate that although IFN-β enhances the primary immune response
(Fig. 3), the adjuvant effect of IFN-β in a viral vaccine vector only
induces minimal long-term beneﬁts as reﬂected by the long-term
memory response.
Discussion
Here we have analyzed the effect of IFN-β on viral replication,
primary CD8+ T cell activation, and memory T cell development in
order to assess its use as amolecular adjuvant in vaccine development.
We see that IFN-β expression efﬁciently decreases the viral titer and
reduces vector pathogenicity (Figs. 2 and 3A). Therefore, IFN-β could
be added to RV-based vaccine vectors to reduce vector-associated
pathogenicity and to increase safety. Furthermore, the anti-viral
activity of IFN-β could potentially lead to a self-limiting infection,
making it more appealing for use in immuno-compromised indivi-
duals. Increased expression of type I IFN during priming has a
signiﬁcant effect on the cellular immune response. Despite having
signiﬁcantly less viral antigen, there was a signiﬁcantly greater
percentage of activated CD8+ T cells in the spleen at 12 dpi (Fig. 3).
This highlights the potential strength for using IFN-β as an adjuvant invaccine development. Although there is a signiﬁcant effect on the
primary immune response, the memory immune response seems to
be unaffected by the addition of IFN-β into the RV vaccine vector (Fig.
8). We hypothesize that the anti-viral activity of IFN-β during priming
counterbalanced the immune-enhancing capability of IFN-β and thus
no signiﬁcant increase on memory cell formation was achieved.
The RV vaccine vector has already been shown to be safe
(McGettigan et al., 2003b; McKenna et al., 2007), but here we show
that the addition of IFN-β into the genome can work to further
attenuate the virus. The recombinant IFN(+) and IFN(−) viruses were
attenuated compared to the parental BNSP-Gag as seen by the 10-
fold reduction in titer at all time points in the growth curve (Fig. 2).
Viral replication was signiﬁcantly decreased in an IFN-β dependent
manner, reafﬁrming the anti-viral effects of type I IFN on negative-
sense RNA viruses (Randall and Goodbourn, 2008). Both the
addition of a second gene into the RV genome and the anti-viral
activity of IFN-β attenuated the RV vaccine vector. This attenuation
was seen in vivo as an increased survival of IFN(+) immunized mice
(Fig. 3A).
In addition to attenuating the virus, we saw that IFN-βwas able to
signiﬁcantly increase the cellular immune response following immu-
nization. Surprisingly, we saw that at 12 dpi CD8+ T cell activationwas
signiﬁcantly greater following infection with the IFN(+) virus, despite
the noted 100-fold decrease in viral load. Furthermore, with 1000-fold
less virus in the brain at 8 dpi, therewas still an equal activated CD8+ T
cell response. Both of these facts indicate that IFN-β is a potent
adjuvant for cellular immunity. Furthermore, the studies in IFNAR−/−
mice indicate that the differences seen here are type I IFN dependent.
This data supports the use of IFN-β to enhance the immune response
to vaccine vectors that are given even at a low MOI.
Fig. 7. The direct effect of IFN-β on CD8+ Tcells. (A) The experimental design is shown here. Brieﬂy, CD3+ Tcells from BALB/c or IFNAR−/−micewere transferred into Nudemice, and at
one day post-transfer, mice were immunized intramuscularly with IFN(+). At 12dpi, the percentage of activated (CD44hi CD62Llo) CD8+ T cells (B) and the total cell number of CD4+
and CD8+ cells recovered from the spleen (C) was determined by ﬂow cytometry. Horizontal lines indicate the average value.
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we sought to determine the mechanism by which IFN-β was
increasing the primary CD8+ T cell response following immuniza-
tion with the IFN(+) virus. In our hands, APC activation does not
seem to be affected by increased levels of IFN-β. Infection with RV
however is not the only viral infection that induces APC maturation
in a type I IFN independent manner. Similarly, DC maturation
following Sendai virus infection has been shown to work
independently of the IFN pathway (Lopez et al., 2003). Although
a strong correlation between DC maturation and type I IFN
induction was observed, it was determined using anti-IFN anti-
bodies that the secreted IFN was neither necessary, nor sufﬁcient to
induce full DC maturation (Lopez et al., 2003). Furthermore, it was
seen that, following adenovirus infection, type I IFN was necessary
for DC to undergo full maturation. However, both wildtype and
IFNAR−/− mice could mount a strong antigen-speciﬁc CD8+ T cell
response (Hensley et al., 2005). Therefore, it is not surprising that
the differences we saw in CD8+ T cell activation in the presence or
absence of exogenous IFN-β were not functions of DC and
macrophage activation.
Instead, the immune-enhancing activity of IFN-β in our vaccine
strategy seems to directly impact CD8+ T cells. Although our transfer
experiment does not deﬁnitively prove that IFN-β is needed to
sustain a population of antigen-speciﬁc CD8+ T cells, the experiment
supports this conclusion. Therefore, it is likely that IFN-β signaling
through a receptor on a CD8+ T cell is required either as a signal to
promote differentiation of effector cells or as a signal to resist
activation-induced cell death. It was seen that IFN-α or IL-12
treatment was required during naïve CD8+ cell priming to induce
proliferation and cytolytic activity. Beads coated with MHC I-peptide
and CD80 co-stimulatory ligand are unable to sufﬁciently prime
naïve CD8+ T cells. However, T cells stimulated by the same beads inthe presence of IFN-α/β are capable of cytolytic function and IFN-γ
production (Curtsinger et al., 2005). On the other hand, IFN-α/β can
also prevent activation-induced cell death of T cells following non-
speciﬁc activation with staphylococcal enterotoxin B (Marrack et al.,
1999). Our model does not allow us to distinguish between these
two possibilities; however, it is in support of a direct role for IFN-β
during priming. This piece of evidence is important and should be
considered during vaccine development.
Despite the undeniable adjuvant effect induced by IFN-β that we
saw during the primary immune response, we did not see a
signiﬁcant increase in antigen-speciﬁc cells following vv-Gag
challenge months later. However, there was much less antigen at
the site of viral replication (the brain) in these mice. It has been
suggested that there exists a diverse repertoire of T cells to a single
epitope and that antigen load can inﬂuence in vitro recall responses
(Naumov et al., 2006). Furthermore, the antigen dose can inﬂuence
the quality of the CD8+ T cell that is induced following infection. In
a study done by Alexander-Miller it was seen that higher avidity
cells were induced at lower peptide concentrations. However, it was
also observed that lower avidity T cells preferentially survived into
memory cells (Alexander-Miller, 2000). Therefore, since memory cell
differentiation is also impacted by the amount of antigen, the
immune-enhancing effects of IFN-β may be counterbalanced by low
antigenic loads, thus yielding a minimal change to the overall
memory cell development. Thus, IFN-β may be a better adjuvant
choice in a DNA or subunit vaccine where the vaccine vector is not
deleteriously impacted by the cytokine.
Another consideration to be made is that type I IFN has been
reported to have different effects on T cells in various activation
states. The result of IFN-α/β signaling in an activated T cells is
different then the response in a naïve T cell. Naïve human CD4+ T
cells that were pre-treated with IFN-α had a delayed entry into the
Fig. 8. The effect of IFN-β on HIV-1 Gag speciﬁc recall response following intramuscular immunization with either IFN(+) or IFN(−) vaccine vector. Mice immunized intramuscularly
with either the IFN(+) or IFN(−) virus were rested for approximately 60 days and then challenged with vaccinia-expressing HIV-1 Gag (VV-Gag). Splenocytes and ovaries were
harvested 5 days post challenge. (A) The percentage of tetramer positive cells in the CD8+ population in mice primed with the IFN(+) or IFN(−) viruses is not signiﬁcantly different. (B)
Splenocytes were stimulated for 16 h with HIV-1 Gag peptide AMQMLKETI, and then a panel of cytokines was analyzed. Data is shown as fold increase over the unstimulated sample.
Horizontal lines indicate the average value.
235E.J. Faul et al. / Virology 382 (2008) 226–238cell cycle. On the other hand, the presence of IFN-α following non-
speciﬁc stimulation of human CD4+ T cells with anti-CD3/ anti-
CD28 antibodies did not inhibit T cell proliferation (Dondi et al.,2003). This study did not however consider how type I IFN affects
CD8+ T cells or memory precursor T cells. Thus, despite the positive
impact that IFN-β had on effector cells during priming, little can be
236 E.J. Faul et al. / Virology 382 (2008) 226–238concluded as to whether or not IFN-β had the same effect on
memory precursor cells.
Materials and methods
Plasmid construction
The gene encoding mouse IFN-β, pORF-mIFNB (Invitrogen),
was used as a template and was ampliﬁed by PCR using Vent
polymerase (New England Biolabs Inc.) and the primers 5′-
TTTCGTACGATCATGAACAACAGGTGGATCCTC-3′ and 5′-AAAGC-
TAGCTC AGTTTTGGAAGTTTCTGGTAAG-3′ containing the BsiWI
or NheI restriction sites (underlined). The resulting PCR fragment
was gel puriﬁed and digested with BsiWI and NheI. The digestion
products were ligated into a plasmid encoding recombinant RV
vaccine vector, pSPBN (McGettigan et al., 2003b), which had been
previously digested with BsiWI and NheI. The resulting plasmid
was designated pSPBN-IFN(+). Alternatively, mouse IFN-β was
ampliﬁed by PCR using the primers 5′-TTTCGTACGATCAACAA-
CAGGTGGATCC TCCAC-3′ and 5′-AAAGCTAGCTCAGTTTTG-
GAAGTTT CTGGTAAG-3′ containing the BsiWI or NheI restriction
sites (underlined) and lacking the ATG start codon. The PCR
fragment was gel puriﬁed, BsiWI and NheI digested, and ligated
into the BsiWI/NheI-digested pSPBN. The resulting plasmid was
designated pSPBN-IFN(−). The plasmid encoding a recombinant RV
vaccine vector expressing HIV-1 Gag (pBNSP-Gag) has been
described previously (McGettigan et al., 2001). The pSPBN-IFN(+)
and pSPBN-IFN(−) plasmids were digested with Pml I and Nco I.
The digestion fragment containing either the IFN(+) or IFN(−) gene
was ligated into pBNSP-Gag previously digested with Pml I and Nco
I. The generated plasmids were designated IFN(+) and IFN(−),
respectively. The introduced sequence for each plasmid was
conﬁrmed by sequencing.
Recovery of recombinant viruses
Recombinant RV virions were recovered by a system described
previously (Tan et al., 2007). Brieﬂy, FuGENE 6 Transfection Reagent
(Roche Diagnostics) was used to co-transfect 6 plasmids into BSR
cells (a BHK-21 cell clone) in 6-well plates. The concentrations of
plasmids (per plate) were as follows: 2.5 μg recombinant RV cDNA,
1.25 μg RV-N, 0.75 μg T7 polymerase, 0.63 μg RV-P and RV-L, and
0.5 μg RV-G. The plasmids encoding the recombinant RV cDNA and
RV-N, P, G, and L were under the control of the T7 promoter (Finke
et al., 2003); the plasmid encoding the T7 polymerase was under
the control of the chicken actin promoter with an enhancer from
the CMV immediate early gene. 3–7 days after transfection the
supernatant was collected from each well and BSR cells were
stained with a ﬂuorescein isothiocyanate (FITC)-conjugated anti-RV-
N antibody (Centacor, Inc.) to identify wells with infectious virus.
Supernatant from RV-positive wells was used to infect a T25 ﬂask
of BSR cells and increase the viral yield.
Immunostaining
BSR cells were infected at a multiplicity of infection (MOI) of
0.01 with either BNSP, IFN(+) or IFN(−) for 48 h. The media was
then aspirated, and the cells were ﬁxed with 80% acetone for
30 min at 4 °C. Cells were washed with PBS and stained with a
human monoclonal antibody for HIV-1 p24 (NIH AIDS Research &
Reference Reagent Program, antibody 71–31) for 60 min at RT. Cells
were washed with PBS and then stained with the secondary
antibody Cy2-conjugated donkey anti-human IgG (Jackson Immu-
noresearch) at a ﬁnal concentration of 5 μg/ml. Alternatively,
infected cells were ﬁxed with 80% acetone and stained with FITC-
conjugated anti RV-N (Centacor, Inc) for 1 h at 37 °C. Stained cellswere washed with PBS and ﬂuorescence was observed under a UV
microscope.
Inhibition of vesicular stomatitis virus (VSV) replication by type I IFN
BSR cells were infected at an MOI of 0.1 with either BNSP, IFN(+) or
IFN(−) for 72 h or left uninfected. Supernatant was collected, spun at
1,600 rpm for 10 min to remove any cellular debris, and then UV-
inactivated (115 V, 60 Hz.16A) for 40 min. UV-inactivated viral
supernatant from BNSP, IFN(+) or IFN(−) infected cells was diluted in
RPMI-1640 1:10 or 1:1000 and added to neuroblastoma (NA) cells.
Following the 24 h pre-treatment, NA cells were infected with VSV-
GFP at an MOI of 5 for 5 h. VSV replication was determined by
ﬂuorescence under a UV light source.
One-step and multi-step growth curves
BSR and NA cells were infected with BNSP-Gag, IFN(+) or IFN(−) in
serum-free media at a MOI of 10 (for the one-step growth curve) or of
0.01 (for themulti-step growth curve). Following 90min incubation at
37 °C, the virus was aspirated, and cells werewashed twicewith PBS to
remove any virus that had not yet infected the cells. Serum-containing
mediawas then added to the cells, and, at indicated time points, 0.3 ml
of supernatant was removed and stored at 4 °C. The aliquots were
titered in duplicate on BSR cells.
Mice
6–8 week old BALB/c mice or IFNAR−/− mice on the BALB/c
background (Martinez-Sobrido et al., 2006) were maintained at the
Thomas Jefferson University Animal Facilities. Mice were infected
either intramuscularly or intranasally with sucrose puriﬁed IFN(+) or
IFN(−) virus. The weight of the mice was monitored daily, and the
animals were euthanized after losing 25% of their body weight and/
or showing severe clinical signs of rabies. Alternately, immunized
mice were euthanized at 8, 12, or 15 days post infection (dpi) to
analyze viral loads and parameters of the immune response. Serum,
brain, and spleen were harvested at each time point for further
analysis.
Mice in the recall response experiments were rested at least
60 days after intramuscular immunization with IFN(+) or IFN(−) and
then were challenged intraperitoneally (I.P.) with 106 pfu of
recombinant vaccinia-expressing HIV-1 Gag. Mice were euthanized
5 days after challenge, and their spleens were harvested for further
analysis.
For the transfer experiments CD3+ cells were isolated from the
spleens of BALB/c or IFNAR−/− mice by a Dynal T cell negative
isolation kit (Invitrogen) according to the manufacturers protocol.
The purity of CD3+ cells was assessed by ﬂow cytometry and
determined to be N90%. 3×106 CD3+ cells were transferred into
Nude mice I.P. One day after transfer, mice were infected with
106 ffu IFN(+) intramuscularly. Mice were euthanized 12 days after
immunization, and their spleens were harvested for further
analysis.
IFN-β and RV-G enzyme-linked immunosorbent assays (ELISA)
For the IFN-β ELISA, BSR cells were infected with IFN(+) or IFN(−)
at an MOI of 0.5 or left uninfected for 48 h. Supernatant was collected
and spun at 1,600 rpm to remove any cellular debris. Viral
supernatant was diluted 1:1000, 1:2000, 1:4000, 1:8000, or
1:16,000 and the amount of IFN-β in each sample was quantiﬁed
using a mouse IFN-β ELISA kit (PBL Biomedical Laboratories)
according to the manufacturer's protocol. RV-G ELISA was done as
described previously (McGettigan et al., 2001). Brieﬂy, Maxisorb
plates (Nunc) were coated with 200 ng/ml puriﬁed RV-G protein
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PBS and blocked with 5% milk/PBS for 30 min at RT. Serum collected
from RV-infected mice at various time points post infection was
diluted in PBS and added to the plate in duplicate. Following a 1 h
incubation at RT, the plate was washed with 0.1% Tween PBS. Goat
anti-mouse IgG conjugated-HRP (Southern Biotech) was added at a
ﬁnal concentration of 200 ng/ml, and plates were incubated at 37 °C
for 30 min. Plates were washed with 0.1% Tween PBS and developed
with o-phenylenediamine dihydrochloride fast tablet peroxidase
substrate (Sigma) for 20 min. The colorimetric reaction was stopped
with 3 M H2SO4, and the absorbance for each well was determined at
490 nm.
Quantitative real time PCR
Virus load in the brains of infected mice was determined by
TaqMan probe-based real time PCR as described previously (Tan et al.,
2007) with the following modiﬁcation: For genomic RNA, samples
were standardized with the equation (y = −3.2211x + 38.394,
R2=0.9999), and for RV messenger RNA samples were standardized
with the equation (y=−3.1406x+36.764, R2=0.9996). The copy
number was normalized to 1 μg/μl total RNA.
Flow cytometry
For surface staining of splenocytes, spleens from infected mice
were homogenized, and a single-cell suspension was prepared.
Erythrocytes were removed with ACK lysing buffer (Sigma Inc), and
splenocytes were counted by trypan blue exclusion. Cells were
washed in FACS buffer (2% BSA/PBS) and blocked on ice for 1 h with
2 μl rat anti-mouse CD16/CD32 (Fc block) (BD Biosciences Pharmi-
gen) and 3.3 μl unconjugated streptavidin in 100 μl FACS. Cells were
washed in FACS buffer and then stained with ﬂuorescent antibodies
for 30 min at RT. After staining, cells were washed with FACS buffer
and ﬁxed with Cytoﬁx (BD Biosciences) for 16–18 h at 4 °C.
For internal staining of splenocytes, samples were stimulated
with 10 μg/ml of AMQMLKETI peptide or left unstimulated for 16 h.
GolgiBlock (BD Bioscience) was added for 6 h and then cells were
stained as above for any surface molecules. Following ﬁxation, cells
were washed twice in Perm/Wash Buffer (BD Bioscience). They
were then stained for 30 min at room temperature for internal
molecules.
For staining of the APC cell lines, at various time points post
infection (MOI=10) cells were collected and blocked on ice for 30 min
with 2 μl Fc block (BD Biosciences Pharmigen) in 100 μl FACS. Cells
were washed twice in Perm/Wash Buffer (BD Bioscience) and then
stained with ﬂuorescent antibodies for 30 min at RT. After staining,
cells were washed with FACS buffer and ﬁxed with Cytoﬁx (BD
Biosciences) for 16–18 h at 4 °C.
Antibodies used include: PE-AMQMLKETI tetramer (Becton Dick-
inson), FITC-CD44, PerCP-CD8α, APC-CD62L, FITC-CD4, PE-CD80, PE-
CD86, FITC-IFN-γ, APC-TNF-α, APC-IL-2, PE-IL-4, PE-IL-6, FITC-IL-10
(BD Biosciences Pharmingen), and RV-N (Centacor, Inc). All samples
were analyzed on BD FACS Calibur 100,000–150,000 events were
counted for splenocyte samples and 50,000 events were counted for
APC cell lines.
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